Juvenile-onset Systemic Lupus Erythematosus: Recent Advances in Pathogenesis and Treatment.
This review of juvenile-onset systemic lupus erythematosus (jSLE) reports that rare gene variants and immune pathway dysregulation converge to explain the disease's heterogeneity, and that the treatment landscape has broadened with the first two approved biologics (belimumab and anifrolumab), protein kinase inhibitors, multitarget lupus nephritis induction regimens, and early CD19-directed CAR-T experience in refractory disease.
Background
Juvenile-onset systemic lupus erythematosus (jSLE) is a heterogeneous autoimmune disease of childhood in which management has traditionally been extrapolated from adult practice. This review summarises recent advances in understanding of its pathogenesis and therapeutic landscape, focusing on how emerging genetic and immunologic insights can inform patient stratification, targeted treatment, and Treat-to-Target (T2T) approaches in paediatric care.
Genetic and immunologic insights
Studies of rare and ultra-rare gene variants — including those affecting TLR7, UNC93B1, PLD4, PTPN2 and BACH2 — have helped delineate key pathogenic pathways and link them to associated clinical phenotypes. Multi-ancestral genomic studies and cumulative genetic metrics are refining the relationships between patient ancestry, disease expression, and genetic burden and variability, which the authors present as support for more personalised management. The review concludes that converging genetic variants and immune pathway dysregulation underlie the heterogeneity of jSLE.
Treatment advances
The therapeutic armamentarium has expanded with the approval of the first two biologic agents for SLE, belimumab and anifrolumab, alongside emerging molecular therapies such as protein kinase inhibitors including JAK inhibitors. New approaches to lupus nephritis induction use multitarget regimens that combine standard therapy with belimumab or with calcineurin inhibitors. Early experience with CD19-directed CAR-T cells is described as promising in refractory SLE, with reported efficacy, sustained drug-free remission and good short-term safety; the authors note that long-term outcomes remain under evaluation.
Clinical implications
Paediatric Treat-to-Target strategies have been adapted to jSLE, and achievement of these targets is reported to be associated with improved disease control and reduced long-term damage. The authors identify future priorities as integrating genomic stratification into routine clinical practice and conducting dedicated paediatric trials of novel targeted therapies, since much of the current evidence for these agents derives from adult populations.
Category
News
Source
Curr Rheumatol Rep
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.